BriaCell advances Bria-MEL+ toward clinical development
BriaCell reported a genetic engineering milestone for Bria-MEL+, advancing its personalized whole-cell melanoma vaccine program toward clinical development.
Bria-MEL+ uses premanufactured cell lines selected via a saliva-based HLA match, aiming to avoid patient-by-patient manufacturing.
Development work has started to support production for potential clinical use, positioning Bria-MEL+ as an expansion beyond breast cancer programs.
The pipeline centers on Bria-IMT in a pivotal Phase 3 metastatic breast cancer trial; Bria-PROS+ received FDA clearance to begin testing.
Melanoma incidence is projected at about 112,000 U.S. cases in 2026, with 8,510 expected deaths, underscoring the target market.
BCTX•
